Abstract:Objective: Multiple myeloma (MM) is an incurable haematological cancer characterized by abnormal proliferation of plasma cells. The promising therapeutic effect of selective inhibitors of nuclear export in MM reveals the broad therapeutic prospects of nuclear localization intervention. Sterol regulatory element binding protein 2 (SREBP2) is a lipid regulatory molecule that has been implicated in the effect of drug therapy for MM. SREBP2 has been reported to be regulated by the antimalarial drug artesunate (ART) through alteration of its nuclear localization and has been shown to inhibit ferroptosis in other tumours. However, the mechanism through which this might occur has not been clarified in MM. Our study aimed to explore whether ART can induce ferroptosis in MM through nuclear localization of SREBP2. Methods: To evaluate whether ferroptosis is induced by treatment with ART in myeloma, we used two types of myeloma cell lines. We first used a series of molecular approaches and other techniques to investigate the impact of ART on cell growth, production of reactive oxygen species (ROS), Fe2+ levels, lipid peroxidation and expression of genes related to ferroptosis. Then, we further explored the mechanism through which ferroptosis may occur in these cells and the relationship between ferroptosis and the nuclear localization of SREBP2. Results: Upregulation of ROS, Fe2+, and lipid peroxidation as well as inhibition of cell growth were observed in myeloma cells after treatment with ART. Expression of acyl CoA synthase long chain family member 4 (ACSL4) was increased, while glutathione peroxidase 4 (GPX4) expression was reduced in cells treated with ART. ART-induced cell death could be reversed by ferropstatin-1 (Fer-1) and deferoxamine mesylate (DFO). Nuclear localization of SREBP2 in myeloma cells was inhibited, accompanied by downregulation of isopentenyl pyrophosphate (IPP) and GPX4, after treatment with ART. Conclusion: In conclusion, our study demonstrated that the antimalarial drug ART can inhibit nuclear localization of SREBP2, downregulate IPP and GPX4, and eventually trigger ferroptosis in myeloma cells. Through this study, we hope to establish a correlation between nuclear localization pathways and mediation of ferroptosis in myeloma cells and provide an innovative direction for exploration-related therapy.

Artesunate-loaded solid lipid nanoparticles resist esophageal squamous cell carcinoma by inducing Ferroptosis through inhibiting the AKT/mTOR signaling

Dual GSH-exhausting Sorafenib Loaded Manganese-Silica Nanodrugs for Inducing the Ferroptosis of Hepatocellular Carcinoma Cells.

A Platinum(iv)-Artesunate Complex Triggers Ferroptosis by Boosting Cytoplasmic and Mitochondrial Lipid Peroxidation to Enhance Tumor Immunotherapy

Folate-modified Erythrocyte Membrane Nanoparticles Loaded with Fe3O4 and Artemisinin Enhance Ferroptosis of Tumors by Low-Intensity Focused Ultrasound

Cancer-Erythrocyte Membrane-Mimicking Fe3O4 Nanoparticles and DHJS for Ferroptosis/Immunotherapy Synergism in Tumors.

Artemisinin Derivatives Inhibit Non-small Cell Lung Cancer Cells Through Induction of ROS-dependent Apoptosis/Ferroptosis

Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma

Ferroptosis: A Novel Mechanism of Artemisinin and Its Derivatives in Cancer Therapy

Enhanced delivery of artesunate by stimuli-responsive polymeric micelles for lung tumor therapy

Artesunate Synergistically Promotes Sorafenib‑induced Apoptosis and Ferroptosis in Non‑hodgkin Lymphoma Cells Through Inhibition of the STAT3 Pathway.

Multifunctional nanoparticles co-loaded with Adriamycin and MDR-targeting siRNAs for treatment of chemotherapy-resistant esophageal cancer

Antitumour effects of artesunate via cell cycle checkpoint controls in human oesophageal squamous carcinoma cells

An Artemisinin-Based Smart Nanomedicine with Self-Supply of Ferrous Ion to Enhance Oxidative Stress for Specific and Efficient Cancer Treatment.

Artemisinin and Salinomycin Co-Loaded Nanozymes to Boost Cascade ROS Accumulation for Augmented Tumor Ferroptosis.

The Effects Of Artesunate On The Expression Of Egfr And Abcg2 In A549 Human Lung Cancer Cells And A Xenograft Model

Potent nanoreactor-mediated ferroptosis-based strategy for the reversal of cancer chemoresistance to Sorafenib

Artesunate induces ferroptosis by inhibiting the nuclear localization of SREBP2 in myeloma cells

Design, synthesis and biological evaluation of artesunate-Se derivatives as anticancer agents by inducing GPX4-mediated ferroptosis

Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in Burkitt's Lymphoma

Artesunate Induces Ferroptosis by Regulating MT1G and Has an Additive Effect with Doxorubicin in Diffuse Large B-cell Lymphoma Cells

Ferroptosis: A New Research Direction of Artemisinin and Its Derivatives in Anti-Cancer Treatment